Page last updated: 2024-08-18

cyclohexanol and Adverse Drug Event

cyclohexanol has been researched along with Adverse Drug Event in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (57.14)	29.6817
2010's	2 (28.57)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Artola, M; Bhatt, AP; Cloer, EW; Davies, GJ; Goldfarb, D; Jariwala, PB; Major, MB; Overkleeft, HS; Pellock, SJ; Redinbo, MR; Roberts, LR; Simpson, JB; Walton, WG	1
Bao, W; Clayton, AH; Guico-Pabia, CJ; Kornstein, SG	1
Ganguly, R; Liebowitz, MR; Manley, AL; Padmanabhan, SK; Tourian, KA; Tummala, R	1
Guico-Pabia, CJ; Jiang, Q; Kornstein, SG; Musgnung, JJ; Reddy, S	1
Hsiao, MC; Lin, YH; Liu, CY	1
Carandang, C; Carrey, N; Gardner, DM; Kutcher, S; Santor, D	1
Hendset, M; Hermann, M	1

Trials

2 trial(s) available for cyclohexanol and Adverse Drug Event

Article	Year
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Current medical research and opinion, 2008, Volume: 24, Issue:7 Topics: Adolescent; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Outpatients; Placebos; Treatment Outcome	2008
Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. The Journal of clinical psychiatry, 2010, Volume: 71, Issue:8 Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Menopause; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Treatment Outcome	2010

Article

Year

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Current medical research and opinion, 2008, Volume: 24, Issue:7

Topics: Adolescent; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Outpatients; Placebos; Treatment Outcome

2008

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

The Journal of clinical psychiatry, 2010, Volume: 71, Issue:8

Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Menopause; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Treatment Outcome

2010

Other Studies

5 other study(ies) available for cyclohexanol and Adverse Drug Event

Article	Year
Discovering the Microbial Enzymes Driving Drug Toxicity with Activity-Based Protein Profiling. ACS chemical biology, 2020, 01-17, Volume: 15, Issue:1 Topics: Animals; Bacterial Proteins; Biomarkers; Computational Biology; Cyclohexanols; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Feces; Female; Gastrointestinal Microbiome; Glucuronidase; Glucuronides; Humans; Hydrolysis; Irinotecan; Kinetics; Male; Metabolome; Mice; Models, Molecular; Precision Medicine; Protein Binding; Protein Conformation	2020
A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. Journal of women's health (2002), 2015, Volume: 24, Issue:4 Topics: Administration, Oral; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Menopause; Middle Aged; Postmenopause; Psychiatric Status Rating Scales; Treatment Outcome	2015
Combined antidepressant and hormone treatment is effective for chemotherapy-induced menopausal syndrome. European psychiatry : the journal of the Association of European Psychiatrists, 2005, Volume: 20, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Contraceptives, Oral, Synthetic; Cyclohexanols; Depressive Disorder; Drug-Related Side Effects and Adverse Reactions; Estrogens; Female; Follicle Stimulating Hormone; Humans; Lymphoma, B-Cell; Medroxyprogesterone; Menopause, Premature; Panic Disorder; Psychiatric Status Rating Scales; Severity of Illness Index; Venlafaxine Hydrochloride	2005
Data safety monitoring boards and other study methodologies that address subject safety in "high-risk" therapeutic trials in youths. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, Volume: 46, Issue:4 Topics: Adolescent; Child; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Human Experimentation; Humans; Male; Research Design; Risk Factors; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted; Treatment Outcome; Venlafaxine Hydrochloride	2007
[Why measure drug metabolites?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2007, Jun-28, Volume: 127, Issue:13 Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Humans; Patient Compliance; Pharmaceutical Preparations; Pharmacogenetics; Risperidone; Venlafaxine Hydrochloride	2007